Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""natalizumab"" wg kryterium: Temat


Tytuł :
Live vaccines and immunosuppressive monoclonal antibodies: weighing up the benefit-risk assessment for natalizumab.
Autorzy :
Schwob JM; Division of Tropical and Humanitarian Medicine, Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Samer CF; Division of Clinical Pharmacology and Toxicology, Department of Acute Medicine, Geneva University Hospitals, Geneva, Switzerland.; Division of Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.; Swiss Centre for Applied Human Toxicology, Geneva, Switzerland.
Lalive PH; Department of Neurosciences, Division of Neurology, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland.; Department of Diagnostic, Division of Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland.
Eperon GA; Division of Tropical and Humanitarian Medicine, Department of Primary Care Medicine, Geneva University Hospitals, Geneva, Switzerland.
Pokaż więcej
Źródło :
Journal of travel medicine [J Travel Med] 2021 Apr 14; Vol. 28 (3).
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal*/adverse effects
Antibodies, Monoclonal*/therapeutic use
Natalizumab*/adverse effects
Natalizumab*/therapeutic use
Vaccines, Attenuated*/adverse effects
Vaccines, Attenuated*/therapeutic use
Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Risk Assessment
Czasopismo naukowe
Tytuł :
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Autorzy :
Mallucci G; Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy. Electronic address: .
Zito A; Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Baldanti F; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; Molecular Virology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Gastaldi M; Neuroimmunology research Unit/Neuroncology and Neuroinflammation Unit, IRCCS Mondino Foundation, Pavia, Italy.
Fabbro BD; Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Franciotta D; Neuroimmunology research Unit, IRCCS Mondino Foundation, Pavia, Italy.
Bergamaschi R; Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy.
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Apr; Vol. 49, pp. 102754. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*/diagnosis
COVID-19*/immunology
Antibodies, Viral/*blood
Fingolimod Hydrochloride/*therapeutic use
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adult ; Asymptomatic Infections ; Female ; Fingolimod Hydrochloride/adverse effects ; Humans ; Male ; Middle Aged ; Multiple Sclerosis/complications ; Natalizumab/adverse effects ; RNA, Viral ; SARS-CoV-2 ; Seroepidemiologic Studies
Czasopismo naukowe
Tytuł :
Vaccine-associated measles in a patient treated with natalizumab: a case report.
Autorzy :
Miauton A; Tropical, travel and vaccination clinic, Unisanté, Center for primary care and public health, Bugnon 44, 1011, Lausanne, Switzerland. .
Tan R; Tropical, travel and vaccination clinic, Unisanté, Center for primary care and public health, Bugnon 44, 1011, Lausanne, Switzerland.
Pantazou V; Department of Neurology, Lausanne University Hospital, Bugnon 46, 1011, Lausanne, Switzerland.
Du Pasquier R; Department of Neurology, Lausanne University Hospital, Bugnon 46, 1011, Lausanne, Switzerland.
Genton B; Tropical, travel and vaccination clinic, Unisanté, Center for primary care and public health, Bugnon 44, 1011, Lausanne, Switzerland.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Oct 14; Vol. 20 (1), pp. 753. Date of Electronic Publication: 2020 Oct 14.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Measles/*etiology
Measles Vaccine/*adverse effects
Measles-Mumps-Rubella Vaccine/*therapeutic use
Natalizumab/*therapeutic use
Adult ; Exanthema/chemically induced ; Female ; Fever/etiology ; Humans ; Immunologic Factors/therapeutic use ; Immunosuppression/adverse effects ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Measles/diagnosis ; Measles Vaccine/therapeutic use ; Measles-Mumps-Rubella Vaccine/adverse effects ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Natalizumab/immunology ; Vaccines, Attenuated/adverse effects ; Vaccines, Attenuated/immunology ; Vaccines, Attenuated/therapeutic use
Czasopismo naukowe
Tytuł :
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
Autorzy :
Khoy K; Laboratory of Immunology, Department of Biology, CHU Caen Normandie, Caen, France.
Mariotte D; Laboratory of Immunology, Department of Biology, CHU Caen Normandie, Caen, France.
Defer G; Department of Neurology, MS Expert Centre, CHU Caen Normandie, Caen, France.; UMR-S1237, Physiopathology and Imaging of Neurological Disorders, INSERM, Caen, France.; Normandie Université, UNICAEN, Caen, France.
Petit G; Laboratory of Immunology, Department of Biology, CHU Caen Normandie, Caen, France.
Toutirais O; Laboratory of Immunology, Department of Biology, CHU Caen Normandie, Caen, France.; UMR-S1237, Physiopathology and Imaging of Neurological Disorders, INSERM, Caen, France.; Normandie Université, UNICAEN, Caen, France.
Le Mauff B; Laboratory of Immunology, Department of Biology, CHU Caen Normandie, Caen, France.; UMR-S1237, Physiopathology and Imaging of Neurological Disorders, INSERM, Caen, France.; Normandie Université, UNICAEN, Caen, France.
Pokaż więcej
Źródło :
Frontiers in immunology [Front Immunol] 2020 Sep 24; Vol. 11, pp. 549842. Date of Electronic Publication: 2020 Sep 24 (Print Publication: 2020).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Molecular Targeted Therapy*
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal/therapeutic use ; Disease Susceptibility ; Drug Monitoring ; Humans ; Integrin alpha4/antagonists & inhibitors ; Leukoencephalopathy, Progressive Multifocal/complications ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/etiology ; Multiple Sclerosis/metabolism ; Natalizumab/pharmacology ; T-Lymphocyte Subsets/drug effects ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
Autorzy :
van Kempen ZLE; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK. .
Hoogervorst ELJ; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Wattjes MP; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Kalkers NF; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Mostert JP; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Lissenberg-Witte BI; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
de Vries A; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Ten Brinke A; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
van Oosten BW; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Barkhof F; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Teunissen CE; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Uitdehaag BMJ; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Rispens T; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Killestein J; From the Department of Neurology, Amsterdam MS Center (Z.L.E.v.K., B.W.v.O., B.M.J.U., J.K.), Department of Radiology (M.P.W., F.B.), and Neurochemistry Lab and Biobank, Department of Clinical Chemistry (C.E.T.), Amsterdam Neuroscience, and Department of Epidemiology and Biostatistics (B.I.L.-W.), Amsterdam University Medical Centers, Vrije Universiteit; Department of Neurology (E.L.J.H.), St. Antonius Hospital, Utrecht, the Netherlands; Department of Diagnostic and Interventional Neuroradiology (M.P.W.), Hannover Medical School, Germany; Department of Neurology (N.F.K.), OLVG Hospital, Amsterdam; Department of Neurology (J.P.M.), Rijnstate Hospital, Arnhem; Biologics Lab, Bioanalysis (A.d.V.), Sanquin Diagnostic Services; Department of Immunopathology (A.t.B., T.R.), Sanquin Research, Amsterdam; Landsteiner Laboratory (A.t.B., T.R.), Academic Medical Centre, University of Amsterdam, the Netherlands; and UCL Institutes of Neurology & Healthcare Engineering (F.B.), Queen Square, London, UK.
Pokaż więcej
Źródło :
Neurology [Neurology] 2020 Aug 11; Vol. 95 (6), pp. e745-e754. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Multiple Sclerosis/*drug therapy
Natalizumab/*administration & dosage
Adult ; Disability Evaluation ; Drug Administration Schedule ; Drug Monitoring ; Female ; Follow-Up Studies ; Humans ; Integrin alpha4beta1/antagonists & inhibitors ; Integrin alpha4beta1/immunology ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis/blood ; Multiple Sclerosis/diagnostic imaging ; Natalizumab/blood ; Natalizumab/therapeutic use ; Netherlands ; Neuroimaging ; Precision Medicine ; Prospective Studies ; Severity of Illness Index
Czasopismo naukowe
Tytuł :
Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis.
Autorzy :
Deslandes MQ; Hospital Universitário Gaffrée e Guinle, Rio de Janeiro, Brazil.
Alves PT; Hospital Universitário Gaffrée e Guinle, Rio de Janeiro, Brazil.
Alvarenga MP; Hospital Federal Gaffré e Guinle and Hospital Federal da Lagoa, Rio de Janeiro, Brazil.
Lessa VCC; Hospital Universitário Gaffrée e Guinle, Rio de Janeiro, Brazil.
Camargo S; Hospital Federal da Lagoa, Rio de Janeiro, Brazil.
Alvarenga RMP; Hospital Federal Gaffré e Guinle and Hospital Federal da Lagoa, Rio de Janeiro, Brazil.
Vasconcelos CC; Hospital Universitário Gaffrée e Guinle, Rio de Janeiro, Brazil. Electronic address: .
Pokaż więcej
Źródło :
Clinical therapeutics [Clin Ther] 2020 Jul; Vol. 42 (7), pp. 1292-1301. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Immunologic Factors/*therapeutic use
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adult ; Brazil ; Cohort Studies ; Female ; Humans ; Immunologic Factors/adverse effects ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis/diagnostic imaging ; Natalizumab/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab.
Autorzy :
Dominguez-Mozo MI; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain.
Perez-Perez S; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain.
Villar LM; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Oliver-Martos B; UGC Neurociencias. Hospital Regional Universitario de Málaga/Instituto de Biomedicina de Málaga (IBIMA), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Villarrubia N; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Matesanz F; Departmento de Biología Celular E Inmunología, Instituto de Parasitología Y Biomedicina López Neyra (IPBLN)/Consejo Superior de Investigaciones Científicas (CSIC), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Costa-Frossard L; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Pinto-Medel MJ; UGC Neurociencias. Hospital Regional Universitario de Málaga/Instituto de Biomedicina de Málaga (IBIMA), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
García-Sánchez MI; UGC Neurología (Biobanco Hospitalario), Hospital Universitario Virgen Macarena, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Ortega-Madueño I; Servicio de Análisis Clínicos, Hospital Clínico San Carlos, Madrid, Spain.
Lopez-Lozano L; Servicio de Análisis Clínicos, Hospital Clínico San Carlos, Madrid, Spain.
Garcia-Martinez A; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain.
Izquierdo G; UGC Neurología, Hospital Universitario Virgen Macarena, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Fernández Ó; UGC Neurociencias. Hospital Regional Universitario de Málaga/Instituto de Biomedicina de Málaga (IBIMA), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Álvarez-Cermeño JC; Servicio de Inmunología, Hospital Universitario Ramón Y Cajal/Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Arroyo R; Departamento de Neurología, Hospital Universitario Quironsalud Madrid, Red Española de Esclerosis Múltiple (REEM), Madrid, Spain.
Alvarez-Lafuente R; Grupo de Investigación de Factores Ambientales en Enfermedades Degenerativas, Pabellón B. Laboratorio Investigación Esclerosis Múltiple, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC)/Hospital Clínico San Carlos, Red Española de Esclerosis Múltiple (REEM), C/ Martín Lagos S/N, 28040, Madrid, Spain. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Aug 28; Vol. 10 (1), pp. 14244. Date of Electronic Publication: 2020 Aug 28.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Pharmacological/*analysis
Multiple Sclerosis/*drug therapy
Natalizumab/*therapeutic use
Adult ; Antibody Formation ; Biomarkers, Pharmacological/blood ; Capsid Proteins/analysis ; Capsid Proteins/immunology ; Disease Progression ; Epstein-Barr Virus Infections/immunology ; Epstein-Barr Virus Nuclear Antigens/analysis ; Female ; HLA Antigens/analysis ; Herpesvirus 4, Human/immunology ; Herpesvirus 6, Human/immunology ; Humans ; Immunoglobulin G/analysis ; Longitudinal Studies ; Male ; Middle Aged ; Multiple Sclerosis/immunology ; Natalizumab/metabolism ; Prognosis ; Recurrence ; Retrospective Studies ; Spain
Czasopismo naukowe
Tytuł :
Lifestyle, exercise and activity package for people living with progressive multiple sclerosis (LEAP-MS): protocol for a single-arm feasibility study.
Autorzy :
Latchem-Hastings, Julie (AUTHOR)
Randell, Elizabeth (AUTHOR)
Button, Kate (AUTHOR)
Jones, Fiona (AUTHOR)
Lowe, Rachel (AUTHOR)
Dawes, Helen (AUTHOR)
Wood, Fiona (AUTHOR)
Davies, Freya (AUTHOR)
Poile, Vincent (AUTHOR)
O'Halloran, Rhian (AUTHOR)
Stensland, Barbara (AUTHOR)
Tallantyre, Emma (AUTHOR)
Playle, Rebecca (AUTHOR)
Edwards, Adrian (AUTHOR)
Busse, Monica (AUTHOR)
Pokaż więcej
Źródło :
Pilot & Feasibility Studies. 5/22/2021, Vol. 7 Issue 1, p1-14. 14p.
Czasopismo naukowe
Tytuł :
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
Autorzy :
Papp, Viktoria (AUTHOR)
Buron, Mathias Due (AUTHOR)
Siersma, Volkert (AUTHOR)
Rasmussen, Peter Vestergaard (AUTHOR)
Illes, Zsolt (AUTHOR)
Kant, Matthias (AUTHOR)
Hilt, Claudia (AUTHOR)
Mezei, Zsolt (AUTHOR)
Roshanisefat, Homayoun (AUTHOR)
Sejbæk, Tobias (AUTHOR)
Weglewski, Arkadiusz (AUTHOR)
van Wingerden, Janneke (AUTHOR)
Geertsen, Svend Sparre (AUTHOR)
Bramow, Stephan (AUTHOR)
Sellebjerg, Finn (AUTHOR)
Magyari, Melinda (AUTHOR)
Pokaż więcej
Źródło :
PLoS ONE. 5/18/2021, Vol. 16 Issue 5, p1-16. 16p.
Czasopismo naukowe
Tytuł :
Patient decision aid based on multi-criteria decision analysis for disease-modifying drugs for multiple sclerosis: prototype development.
Autorzy :
Kremer, I. E. H. (AUTHOR)
Jongen, P. J. (AUTHOR)
Evers, S. M. A. A. (AUTHOR)
Hoogervorst, E. L. J. (AUTHOR)
Verhagen, W. I. M. (AUTHOR)
Hiligsmann, M. (AUTHOR)
Pokaż więcej
Źródło :
BMC Medical Informatics & Decision Making. 4/9/2021, Vol. 21 Issue 1, p1-18. 18p.
Czasopismo naukowe
Tytuł :
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
Autorzy :
De Mercanti SF; Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Torino, Italy. Electronic address: .
Signori A; Department of Health Sciences, Section of Biostatistics, University of Genova, Italy.
Cordioli C; Multiple Sclerosis Center, Spedali Civili of Brescia, Presidio di Montichiari, Brescia, Italy.
Signoriello E; Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy.
Lus G; Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, Second University of Naples, Italy.
Bonavita S; Clinic of Neurology, AOU - University of Campania 'Luigi Vanvitelli', Napoli, Italy.
Abbadessa G; Clinic of Neurology, AOU - University of Campania 'Luigi Vanvitelli', Napoli, Italy.
Lavorgna L; Clinic of Neurology, AOU - University of Campania 'Luigi Vanvitelli', Napoli, Italy.
Maniscalco GT; Neurological Clinic and Multiple Sclerosis Centre of 'AORN A.Cardarelli', Naples, Italy.
Curti E; Neurology Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Lorefice L; Multiple Sclerosis Center, Binaghi Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Cocco E; Multiple Sclerosis Center, Binaghi Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Nociti V; Multiple Sclerosis Center, Neuroscience Area, Neuroscience, Aging, Head and Neck and Orthopaedics Sciences Department, Fondazione Policlinico Universitario Gemelli, Roma, Italy.
Mirabella M; Multiple Sclerosis Center, Neuroscience Area, Neuroscience, Aging, Head and Neck and Orthopaedics Sciences Department, Fondazione Policlinico Universitario Gemelli, Roma, Italy.
Baroncini D; Centro Sclerosi Multipla - Presidio ospedaliero di Gallarate - ASST Valle Olona, Italy.
Mataluni G; UOSD Centro di Riferimento Regionale Sclerosi Multipla - Dipartimento di Neuroscienze Policlinico Tor Vergata, Roma, Italy.
Landi D; UOSD Centro di Riferimento Regionale Sclerosi Multipla - Dipartimento di Neuroscienze Policlinico Tor Vergata, Roma, Italy.
Petruzzo M; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Multiple Sclerosis Centre, Federico II University, Naples, Italy.
Lanzillo R; Department of Neurosciences, Reproductive Sciences and Odontostomatology, Multiple Sclerosis Centre, Federico II University, Naples, Italy.
Gandoglia I; Dept of Neuroscience, Rehabilititation, Ophthalmology, Genetics, Maternal and Child Health, Center of Excellence for Biomedical Research, University of Genova, Italy.
Laroni A; IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Frangiamore R; Department of Neuroimmunology and Neuromuscular Diseases, Neurological Institute C. Besta, IRCCS Foundation, Milan, Italy.
Sartori A; Neurology Unit, Azienda Sanitaria Univeristaria Integrata Clinica Neurologica, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Trieste, Italy.
Cavalla P; Department of Neuroscience, Città della Salute e della Scienza di Torino University Hospital, Torino, Italy.
Costantini G; Department of Neuroscience, Città della Salute e della Scienza di Torino University Hospital, Torino, Italy.
Capra R; Multiple Sclerosis Center, Spedali Civili of Brescia, Presidio di Montichiari, Brescia, Italy.
Sormani MP; Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Torino, Italy.
Clerico M; Clinical and Biological Sciences Department, Neurology Unit, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Torino, Italy.
Pokaż więcej
Źródło :
Journal of the neurological sciences [J Neurol Sci] 2021 May 15; Vol. 424, pp. 117385. Date of Electronic Publication: 2021 Mar 06.
Typ publikacji :
Journal Article; Multicenter Study; Observational Study
MeSH Terms :
Leukoencephalopathy, Progressive Multifocal*
Multiple Sclerosis*/diagnostic imaging
Multiple Sclerosis*/drug therapy
Multiple Sclerosis, Relapsing-Remitting*
Humans ; Immunologic Factors/adverse effects ; Italy ; Magnetic Resonance Imaging ; Natalizumab/adverse effects ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
Autorzy :
Kågström S; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address: .
Fält A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address: .
Berglund A; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Piehl F; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Olsson T; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Lycke J; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 May; Vol. 50, pp. 102842. Date of Electronic Publication: 2021 Feb 11.
Typ publikacji :
Journal Article
MeSH Terms :
JC Virus*
Leukoencephalopathy, Progressive Multifocal*/chemically induced
Leukoencephalopathy, Progressive Multifocal*/epidemiology
Multiple Sclerosis*/drug therapy
Multiple Sclerosis*/epidemiology
France ; Humans ; Immunologic Factors/adverse effects ; Natalizumab/adverse effects ; Retrospective Studies ; Sweden/epidemiology
Czasopismo naukowe
Tytuł :
Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients.
Autorzy :
van Kempen ZLE; Department of Neurology, MS Center Amsterdam, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands. Electronic address: .
van Rossum JA; Department of Neurology, MS Center Amsterdam, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands.
Hoogervorst E; Department of Neurology, St. Antonius Hospital, Utrecht, the Netherlands.
Strijbis E; Department of Neurology, MS Center Amsterdam, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands.
Toorop A; Department of Neurology, MS Center Amsterdam, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands.
Bosscha MI; Department of Ophthalmology, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands.
Frequin S; Department of Neurology, St. Antonius Hospital, Utrecht, the Netherlands.
Dam-van Loon NT; Department of Ophthalmology, UMC Utrecht, Utrecht, the Netherlands.
Wattjes MP; Department of Radiology, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands; Department of Diagnostic and Interventional Neuroradiology, Hannover Medical School, Hannover, Germany.
Murk JL; Microvida, St. Elisabeth Tweesteden Hospital Tilburg, Tilburg, the Netherlands.
Killestein J; Department of Neurology, MS Center Amsterdam, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands.
Uitdehaag BMJ; Department of Neurology, MS Center Amsterdam, Amsterdam UMC - location VUmc, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 May; Vol. 50, pp. 102838. Date of Electronic Publication: 2021 Feb 10.
Typ publikacji :
Letter
MeSH Terms :
Chickenpox*
Herpes Zoster*/complications
Herpes Zoster*/drug therapy
Retinal Necrosis Syndrome, Acute*/chemically induced
Retinal Necrosis Syndrome, Acute*/drug therapy
Central Nervous System ; Humans ; Natalizumab/adverse effects
Opinia redakcyjna
Tytuł :
Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML.
Autorzy :
Alleg M; Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France. .
Solis M; Hôpitaux universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France.
Baloglu S; Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France.
Cotton F; MRI center, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon,, Lyon, France.; Université Lyon 1, CREATIS-LRMN, CNRS/UMR/5220-INSERM U630, Villeurbanne, France.
Kerschen P; Centre hospitalier de Luxembourg, Luxembourg City, Luxembourg.
Bourre B; Rouen University Hospital, F-76000, Rouen, France.
Ahle G; Service de Neurologie, Hôpitaux Civils de Colmar, Colmar, France.
Pruvo JP; Department of Neuroradiology, University of Lille, Inserm UMR-S 1172, CHU Lille, Lille, France.
Leclerc X; Department of Neuroradiology, University of Lille, Inserm UMR-S 1172, CHU Lille, Lille, France.
Vermersch P; Univ-Lille, Inserm UMR 1172, CHU Lille, FHU Imminent, Lille, France.
Papeix C; Department of Neurology, CRC-SEP, Pitié-Salpêtrière Hospital, APHP, Paris, France.
Maillart É; Department of Neurology, CRC-SEP, Pitié-Salpêtrière Hospital, APHP, Paris, France.
Houillier C; APHP, Sorbonne Université, IHU, ICM, Service de Neurologie 2-Mazarin, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Chabrot CM; CHU de Clermont Ferrand, Clermont Ferrand, France.
Claise B; CHU de Clermont Ferrand, Clermont Ferrand, France.
Malak S; Service d'hématologie, Institut Curie-Saint-Cloud, Saint-Cloud, France.
Martin-Blondel G; Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, Toulouse, France.; UMR INSERM/CNRS 1043, Centre de Physiopathologie Toulouse Purpan, Toulouse, France.
Bonneville F; Service de Neuroradiologie, CHU de Toulouse, Toulouse, France.
Caulier A; Hématologie Clinique, CHU Amiens-Picardie, Amiens, France.
Marolleau JP; Hématologie Clinique, CHU Amiens-Picardie, Amiens, France.
Bonnefoy JT; Hôpital Cochin Paris, Paris, France.
Agape P; Institut de Cancérologie de l'Ouest , Saint-Herblain, Nantes, France.
Kennel C; CHU de Limoges, Limoges, France.
Roussel X; CHU de Besançon, Besançon, France.
Chauchet A; CHU de Besançon, Besançon, France.
De Seze J; Service de Neurologie, Hôpitaux Universitaires de Strasbourg Hôpital de Hautepierre, Strasbourg, France.
Fafi-Kremer S; Hôpitaux universitaires de Strasbourg, Laboratoire de Virologie Médicale, Strasbourg, France.
Kremer S; Hôpitaux Universitaires de Strasbourg, Service d'imagerie 2, Hôpital de Hautepierre, Strasbourg, France.; Engineering Science, Computer Science and Imaging Laboratory (ICube) UMR 7357, University of Strasbourg-CNRS, Strasbourg, France.
Pokaż więcej
Źródło :
European radiology [Eur Radiol] 2021 May; Vol. 31 (5), pp. 2944-2955. Date of Electronic Publication: 2020 Nov 06.
Typ publikacji :
Journal Article
MeSH Terms :
HIV Infections*/complications
HIV Infections*/drug therapy
Leukoencephalopathy, Progressive Multifocal*/chemically induced
Leukoencephalopathy, Progressive Multifocal*/diagnostic imaging
Brain/diagnostic imaging ; Humans ; Magnetic Resonance Imaging ; Natalizumab/adverse effects ; Retrospective Studies ; Rituximab/adverse effects
Czasopismo naukowe
Tytuł :
End of dose interval symptoms in patients treated with natalizumab: A role for serum cytokines?
Autorzy :
Cathérine D; Department of Neurology, UZ Gent, Corneel Heymanslaan 10, Gent, Belgium. Electronic address: .
Annelien P; Department of Neurology, AZ St. Lucas, Groenebriel 1, Gent, Belgium.
Anne S; Department of Neurology, UZ Gent, Corneel Heymanslaan 10, Gent, Belgium; Department of Neurology, AZ Jan Palfijn, Henri Dunantlaan 5, Gent, Belgium.
Luc A; Department of Neurology, AZ Maria Middelares, Buitenring-Sint-Denijs 30, Gent, Belgium.
Liesbeth VH; Department of Neurology, UZ Gent, Corneel Heymanslaan 10, Gent, Belgium.
Gerlo S; VIB Center for Medical Biotechnology, Albert Baertsoenkaai 3, Gent, Belgium; Department of Biomolecular Medicine, UGent, Albert Baertsoenkaai 3, Gent, Belgium.
Guy L; Department of Neurology, UZ Gent, Corneel Heymanslaan 10, Gent, Belgium. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Jun; Vol. 41, pp. 102020. Date of Electronic Publication: 2020 Feb 22.
Typ publikacji :
Journal Article
MeSH Terms :
Outcome Assessment, Health Care*
Cognitive Dysfunction/*drug therapy
Cytokines/*blood
Depression/*drug therapy
Fatigue/*drug therapy
Immunologic Factors/*pharmacology
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Natalizumab/*pharmacology
Adult ; Cognitive Dysfunction/blood ; Cognitive Dysfunction/etiology ; Depression/blood ; Depression/etiology ; Fatigue/blood ; Fatigue/etiology ; Female ; Humans ; Immunologic Factors/administration & dosage ; Interferon-gamma/blood ; Interleukin-6/blood ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting/blood ; Multiple Sclerosis, Relapsing-Remitting/complications ; Natalizumab/administration & dosage ; Recurrence ; Severity of Illness Index ; Tumor Necrosis Factor-alpha/blood
Czasopismo naukowe
Tytuł :
Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use.
Autorzy :
Triplett JD; Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia.
Vijayan S; Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia; The Perron Institute for Neurological and Translational Sciences, QE II Medical Centre, Perth, Australia.
Rajanayagam S; Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia; The Perron Institute for Neurological and Translational Sciences, QE II Medical Centre, Perth, Australia.
Tuch P; Hollywood Private Hospital, Nedlands, Australia.
Kermode AG; The Perron Institute for Neurological and Translational Sciences, QE II Medical Centre, Perth, Australia; Faculty of Medicine, University of Western Australia, Perth, Australia; Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Australia. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 May; Vol. 40, pp. 101961. Date of Electronic Publication: 2020 Jan 30.
Typ publikacji :
Journal Article
MeSH Terms :
Pregnancy Outcome*
Abnormalities, Drug-Induced/*etiology
Anemia/*chemically induced
Immunologic Factors/*adverse effects
Multiple Sclerosis/*drug therapy
Natalizumab/*adverse effects
Pregnancy Complications/*drug therapy
Pregnancy Trimester, Third/*drug effects
Thrombocytopenia/*chemically induced
Adult ; Anemia/congenital ; Female ; Humans ; Infant, Newborn ; Natalizumab/administration & dosage ; Pregnancy ; Retrospective Studies ; Thrombocytopenia/congenital
Czasopismo naukowe
Tytuł :
Disease modifying therapies in relapsing-remitting multiple sclerosis: A systematic review and network meta-analysis.
Autorzy :
Liu Z; Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Liao Q; Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Wen H; Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhang Y; Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Electronic address: .
Pokaż więcej
Źródło :
Autoimmunity reviews [Autoimmun Rev] 2021 Jun; Vol. 20 (6), pp. 102826. Date of Electronic Publication: 2021 Apr 18.
Typ publikacji :
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms :
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Humans ; Immunologic Factors ; Immunosuppressive Agents/therapeutic use ; Natalizumab ; Network Meta-Analysis
Czasopismo naukowe
Tytuł :
Progressive multifocal leukoencephalopathy in the era of new disease-modifying treatments for multiple sclerosis.
Autorzy :
Filippi-Arriaga F; Servei de Farmacologia Clínica, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Riera-Arnau J; Servei de Farmacologia Clínica, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: .
Rodríguez-Acevedo B; Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Unitat de Neuroinmunologia Clínica, Servei de Neurologia, Vall d'Hebron Institut de Recerca (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Bosch Ferrer M; Servei de Farmacologia Clínica, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España.
Pokaż więcej
Transliterated Title :
Leucoencefalopatía multifocal progresiva en la era de los nuevos tratamientos modificadores de la enfermedad para la esclerosis múltiple.
Źródło :
Medicina clinica [Med Clin (Barc)] 2021 May 21; Vol. 156 (10), pp. 509-514. Date of Electronic Publication: 2021 Jan 09.
Typ publikacji :
Journal Article
MeSH Terms :
Leukoencephalopathy, Progressive Multifocal*/chemically induced
Leukoencephalopathy, Progressive Multifocal*/diagnosis
Multiple Sclerosis*/drug therapy
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Humans ; Immunologic Factors ; Natalizumab/adverse effects
Czasopismo naukowe
Tytuł :
Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis.
Autorzy :
Lambe J; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Risher H; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Filippatou AG; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Murphy OC; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Sotirchos ES; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Ehrhardt H; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Ogbuokiri E; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Pellegrini N; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Toliver B; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Luciano NJ; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Davis S; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Fioravante N; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Kwakyi O; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Prince JL; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Calabresi PA; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD.
Fitzgerald KC; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD. .
Saidha S; From the Department of Neurology (J.L., H.R., A.G.F., O.C.M., E.S.S., H.E., E.O., N.P., B.T., N.J.L., S.D., N.F., O.K., P.A.C., K.C.F., S.S.), Johns Hopkins University School of Medicine; and Department of Electrical and Computer Engineering (J.L.P.), Johns Hopkins University, Baltimore, MD. .
Pokaż więcej
Źródło :
Neurology [Neurology] 2021 May 18; Vol. 96 (20), pp. e2525-e2533. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immunologic Factors/*therapeutic use
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Retina/*diagnostic imaging
Retinal Degeneration/*diagnostic imaging
Rituximab/*therapeutic use
Adult ; Atrophy ; Case-Control Studies ; Female ; Glatiramer Acetate/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting/complications ; Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging ; Natalizumab/therapeutic use ; Retinal Degeneration/etiology ; Retinal Ganglion Cells/pathology ; Tomography, Optical Coherence ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Use of an electronic seizure diary in a randomized, controlled trial of natalizumab in adult participants with drug-resistant focal epilepsy.
Autorzy :
Patel J; Biogen, Cambridge, MA, USA. Electronic address: .
Feng W; Biogen, Cambridge, MA, USA. Electronic address: .
Chen K; Biogen, Cambridge, MA, USA. Electronic address: .
French JA; NYU Grossman School of Medicine, New York, NY, USA. Electronic address: .
Rushton M; Biogen, Cambridge, MA, USA. Electronic address: .
Hubbard S; Biogen, Cambridge, MA, USA. Electronic address: .
Ren Z; Biogen, Cambridge, MA, USA. Electronic address: .
Potero E; Biogen, Cambridge, MA, USA. Electronic address: .
Parkerson KA; Biogen, Cambridge, MA, USA. Electronic address: .
Pokaż więcej
Źródło :
Epilepsy & behavior : E&B [Epilepsy Behav] 2021 May; Vol. 118, pp. 107925. Date of Electronic Publication: 2021 Apr 05.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Epilepsies, Partial*/drug therapy
Pharmaceutical Preparations*
Adult ; Anticonvulsants/therapeutic use ; Electronics ; Humans ; Natalizumab/therapeutic use ; Retrospective Studies ; Seizures/drug therapy
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies